POU3F4-DFN3 Locus (Deafness Genetic Test)
| Order Code: | POU3F4 |
| Epic Lab Code: | LAB7329 |
| Order Form: | A-1a Miscellaneous Request or Epic Req |
Commercial Mail-out Laboratory
01250 PFP
356-3527
01250 PFP
356-3527
Specimen:
Whole Blood
Collection Medium:
![]() | and | ![]() |
| Pink top tube | Pink top tube |
Alternate
Collection Media:
Lavender top tube 4 mL (EDTA)
Minimum:
Preferred Minimum: 8 mL whole blood
Absolute Minimum: 4 mL whole blood
Turn Around
Time:
3 months
Reference Range:
None detected
Interpretive Data:
DFN3
Deafness at the DFN3 locus can be conductive (due to impaired stapes
mobility) and/or mixed with a superimposed, often progressive,
sensorineural component. Stapedectomy to correct the conductive
component is contraindicated because of the possibility of iatrogenic
profound hearing loss secondary to a stapes gusher. A stapes gusher
occurs because the internal auditory canal is abnormally dilated. The
wide communication between the internal auditory canal and inner ear
can often be visualized by computerized tomography. The gene, POU3F4,
was found to be responsible for this form of X-linked hearing loss by
De Kok and colleagues.
POU3F4
The single exon of POU3F4 encodes a transcription factor with a 75
amino acid POU domain and a 63 amino acid homeobox domain. In animal
studies, Minowa and colleagues showed Brn4 (Pou3f4) deficient mice have
profound deafness and inner ear abnormalities. In humans with DFN3,
mutations have been found in either of the two binding domains, as well
as upstream of POU3F4. In the presence of these large upsteam
deletions, the coding sequence of POU3F4 can be entirely normal.
Sensitivity is greater than 99% for coding sequence analysis of POU3F4.
The sensitivity of the deletion screen is unknown.
Comments:
Please print, complete and submit the Deafness Testing Requisition from the Molecular Otolaryngology
& Renal Research Laboratory, to Specimen Control/Mailouts with the
specimen and the Epic Requisition.
Methodology:
Screening for POU3F4 is performed by sequencing and STRP analysis. The
initial screening test uses oligonucleotide primers that amplify the
exon of POU3F4 followed by direct sequencing to determine whether
mutations lie within the POU3F4 gene. In the absence of a POU3F4 coding
mutation, the upstream region of POU3F4 is screened for a possible
deletion by running 8 STSs that cover approximately 1200 kB of genomic
DNA at regularly spaced intervals. These markers are PCR amplified,
resolved by gel electrophoresis and scored as present or absent.
CPT Code:
83891, 83894, 83898 (x20), 83904 (x6)
